Literature DB >> 31290113

Assessment of Contraceptive Counseling and Contraceptive Use in Women After Bariatric Surgery.

Michiel A Damhof1, Esther Pierik2, Lisanne L Krens3, Marloes Vermeer4, Marc J van Det5, Eric N van Roon2,6.   

Abstract

BACKGROUND: Reproductive-aged women are, according to American and European guidelines, recommended to avoid pregnancy for 12-24 months after bariatric surgery. Oral contraceptives may have suboptimal efficacy after malabsorptive bariatric procedures. AIM: The aim of this study was to assess contraceptive use pre- and postoperatively in women who underwent bariatric surgery in two obesity clinics in The Netherlands. Also, the recall of contraceptive and pregnancy counseling was investigated.
METHODS: A validated questionnaire was performed among women aged 18-45 years who underwent bariatric surgery from October 2017 through August 2018.
RESULTS: In total, 230 women were eligible for final analysis. Postoperatively, 60% used safe contraception, 16.1% unsafe contraception, and 23.9% no contraception. In this study, 43.7% of women using a potential unsafe contraceptive method preoperatively switched to a safe method of contraception postoperatively (p < 0.0001). Only 62.6% of women confirmed to have received contraceptive counseling, mainly preoperatively. The odds ratio for receiving contraceptive counseling and using safe contraceptive methods compared with not receiving contraceptive counseling was 2.20 (95% CI, 1.27-3.79; p = 0.005). Eighty-three percent confirmed that they have received counseling regarding delaying a pregnancy, and 52.6% were familiar with the recommendation to avoid a pregnancy for 24 months postoperatively.
CONCLUSIONS: In our study, 60% of women are using safe contraception postoperatively. Contraceptive counseling is suboptimal as 62.6% recall receiving counseling. Those who confirmed receiving counseling were more likely to use safe contraception after bariatric surgery. More counseling and monitoring in the postoperative and in the outpatient setting is recommended.

Entities:  

Keywords:  Bariatric surgery; Contraception; Counseling; Gastric bypass; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 31290113     DOI: 10.1007/s11695-019-04084-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  18 in total

1.  National trends in utilization and outcomes of bariatric surgery.

Authors:  T L Trus; G D Pope; S R G Finlayson
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

2.  Pregnancy outcomes after gastric-bypass surgery.

Authors:  Tuoc Dao; Joseph Kuhn; Dale Ehmer; Tammy Fisher; Todd McCarty
Journal:  Am J Surg       Date:  2006-12       Impact factor: 2.565

3.  Pregnancy following gastric bypass for morbid obesity.

Authors:  A C Wittgrove; L Jester; P Wittgrove; G W Clark
Journal:  Obes Surg       Date:  1998-08       Impact factor: 4.129

4.  European society of contraception statement on contraception in obese women.

Authors:  Gabriele S Merki-Feld; Sven Skouby; David Serfaty; Medard Lech; Johannes Bitzer; Pier Giorgio Crosignani; Angelo Cagnacci; Regine Sitruk-Ware
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-11-07       Impact factor: 1.848

5.  Demographics and outcomes at American Society for Metabolic and Bariatric Surgery Centers of Excellence.

Authors:  Gary M Pratt; Chris A Learn; Gail D Hughes; Bobby L Clark; Mike Warthen; Walter Pories
Journal:  Surg Endosc       Date:  2009-01-30       Impact factor: 4.584

6.  Sex hormone levels and intestinal absorption of estradiol and D-norgestrel in women following bypass surgery for morbid obesity.

Authors:  A N Andersen; P E Lebech; T I Sørensen; B Borggaard
Journal:  Int J Obes       Date:  1982

7.  Risk for congenital malformations in offspring of women who have undergone bariatric surgery. A national cohort.

Authors:  A Josefsson; M Bladh; A-B Wiréhn; G Sydsjö
Journal:  BJOG       Date:  2013-08-09       Impact factor: 6.531

8.  Timing of pregnancy after gastric bypass-a national register-based cohort study.

Authors:  Mette Mandrup Kjær; Lisbeth Nilas
Journal:  Obes Surg       Date:  2013-08       Impact factor: 4.129

9.  Contraception, Menstruation, and Sexuality after Bariatric Surgery: a Prospective Cohort Study.

Authors:  Julie Luyssen; Goele Jans; Annick Bogaerts; Dries Ceulemans; Christophe Matthys; Bart Van der Schueren; Matthias Lannoo; Johan Verhaeghe; Luc Lemmens; Lore Lannoo; Jill Shawe; Roland Devlieger
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

10.  Contraceptive Use Before and After Gastric Bypass: a Questionnaire Study.

Authors:  Charlotte Ginstman; Jessica Frisk; Johan Ottosson; Jan Brynhildsen
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

View more
  5 in total

Review 1.  Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.

Authors:  Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2021-06-03       Impact factor: 3.716

2.  Review: Sex-Specific Aspects in the Bariatric Treatment of Severely Obese Women.

Authors:  Pia Jäger; Annina Wolicki; Johannes Spohnholz; Metin Senkal
Journal:  Int J Environ Res Public Health       Date:  2020-04-15       Impact factor: 3.390

3.  The Impact of Bariatric Surgery on Menstrual Abnormalities-a Cross-Sectional Study.

Authors:  Anna Różańska-Walędziak; Paweł Bartnik; Joanna Kacperczyk-Bartnik; Krzysztof Czajkowski; Maciej Walędziak
Journal:  Obes Surg       Date:  2020-07-13       Impact factor: 4.129

Review 4.  Women in larger bodies' experiences with contraception: a scoping review.

Authors:  Tierney M Boyce; Elena Neiterman
Journal:  Reprod Health       Date:  2021-04-29       Impact factor: 3.223

Review 5.  Maternal Nutritional Status and Pregnancy Outcomes Post-bariatric Surgery.

Authors:  Sara H Alamri; Ghalia N Abdeen
Journal:  Obes Surg       Date:  2022-02-15       Impact factor: 4.129

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.